Stay updated with breaking news from Merck Patient Support Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
12.01.2024 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) for the treatment of ...
KEYTRUDA is the first and only anti-PD-1 therapy approved in combination with chemoradiotherapy for these patients Approval marks third FDA-approved indication for KEYTRUDA in cervical cancer and...
Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone Approval marks seventh...
First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients ... | April 3, 2023